TNF-α inhibitors not only improve inflammation-associated bone metabolic disorders but also show therapeutic potential in inflammatory bone loss diseases such as RA, inflammatory bowel disease (IBD), and ankylosing spondylitis (AS) (90, 91). The gene discussed is TNF; the disease is rheumatoid arthritis.